The company does possess a lot of potential, with its approved gene-editing treatment Casgevy. Unfortunately, sales from that ...

The stock has climbed in the double-digits in recent years. Vertex Pharmaceuticals ( VRTX 1.53%) has proven itself to be an excellent long-term investment, advancing 91% over the past five years. This ...

So far, the company's commercialized drugs have delivered billions of dollars in revenue. For example, in the latest quarter, Vertex's revenue soared 11% to more than $3 billion -- that's with net ...

Vertex Pharmaceuticals (NDAQ: VRTX) stands today as a top 20 pharma company with over a $100 billion market cap. But this biotech beacon has ridden a bumpy path to its current perch and, along the way ...

In the latest close session, Vertex Pharmaceuticals (VRTX) was down 1.2% at $449.52. This change lagged the S&P 500's 1.16% loss on the day. Meanwhile, the Dow experienced a drop of 0.47%, and the ...

Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label expansion and stronger commercial uptake.

Vertex Pharmaceuticals presents clinical data demonstrating benefits of Casgevy in SCD and TDT patients aged 5+ at ASH ...

For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the company’s fifth cystic fibrosis treatment Alyftrek and its non-opioid pain relief ...